Replies to post #6 on Immuron Limited (IMRN)

[Kauri]

$25 would only be a fully diluted ASX & Nasdaq shares & options on slightly less than 200mio shares/warrants/options, equates to ~80cents on ASX. Which is $160mio AUD$ or USD$120mio using a AUDUSD cross rate of 0.75.
This is incredibly cheap at $120mio USD. So I'm estimating anything between USD$400mio to $1bio is feasible on good Nash Ph2results & ensuing partnership agreement with big pharma.
Share price at 400/600/800/1bio market caps:
USD$400mio being ~$84 per share on Nasdaq or $2.67 on the Australian ASX
Market cap of USD$600mio being $126 per Nasdaq share or $4 on the ASX
USD$800mio ~$168 on Nasdaq or $5.34 ASX
USD$1bio ~$210, $6.67 on ASX

Personally I think a share price of north of $126 on Nasdaq is easily achievable on positive PH2 NASH & pharma collaboration within a few months afterwards. This also completely ignores the very promising preclinical Cdiff pipeline, which has commenced a Phase 1/2 on 60 patients.

Also on a cash side, Immuron will have funds from warrants & options exercising, & also cash lump sum payment from big pharma collaboration.

Keen to hear your thoughts on the market cap projections. Good luck and let's hope for amazing PH2 Nash results & a fantastic partnering deal with a chunky lump sum.

[otcmoneydoubler]

EXPECTING MEGA RUNS FOR IMRN AND ZSAN. POSITIVE NASH RESULTS WITH NO SERIOUS SIDE EFFECTS COULD BRING SOME ASTRONOMICAL NUMBERS TO IMRN HERE. NASH DISEASE IS NO JOKE. LETS SEE.